Confocal Laser Endomicroscopy with Cellvizio proven superior to X-ray fluoroscopy for the guidance of transbronchial cryobiopsy, offering a...
Strong H1 sales growth (+101%) and significant reduction in current operating loss (-78%) Generated YTD net profit, supported by contribution...
Dr. Jeong Kim Uses Cellvizio to Improve Diagnosis of Gastric Disease Paris and Boston, September 19, 2023 – 8:00 a.m. CEST – Mauna Kea...
Paris and Boston, August 4, 2023 – 8:00 a.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Q2 revenue increased 77% globally, including 100% United States sales growth Pipeline of new potential strategic partnerships continues to...
Paris and Boston, July 3, 2023 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Paris and Boston, June 30, 2023 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Paris and Boston, June 13, 2023 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Paris and Boston, June 8, 2023 – 5:45 PM CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Shareholders approved all proposed resolutions Paris and Boston, June 5, 2023 - 5:45 pm CEST - Mauna Kea Technologies (Euronext: MKEA)...
Study will advance the validation of Cellvizio® as a real-time biopsy guidance tool during robotic-assisted bronchoscopy Paris and Boston,...
Cash position of €6.7m at May 31, 2023 strengthened by USD 2.5m received from the joint venture with Tasly Pharmaceutical Paris and...
